Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.8K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats.

Transplant international : official journal of the European Society for Organ Transplantation·2006
Same author

[Effects of mechanical tensile stress on the expression of ICAM-1 mRNA in osteoblasts differentiated from rBMSCs].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2006
Same author

[Effects of osteoporosis on experimental tooth movement in aged rats].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2006
Same author

MCALIGN2: faster, accurate global pairwise alignment of non-coding DNA sequences based on explicit models of indel evolution.

BMC bioinformatics·2006
Same author

[Managements of masked mastoiditis].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2006
Same author

Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction.

The Journal of biological chemistry·2006
Same journal

Nuclear Receptor-Targeted Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease.

International journal of drug discovery and pharmacology·2026
Same journal

Hippo Signaling: Advances in Potential Therapeutic Targets for Sinoatrial Node Disorders.

International journal of drug discovery and pharmacology·2025
Same journal

Unraveling the Roles of HIF-1, HO-1, GLUT-1 and GLUT-4 in Myocardial Protection.

International journal of drug discovery and pharmacology·2025
Same journal

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4<sup>+</sup>Foxp3<sup>+</sup> Regulatory T Cell Immunosuppression.

International journal of drug discovery and pharmacology·2025
Same journal

The P21-Activated Kinase 1 and 2 As Potential Therapeutic Targets for the Management of Cardiovascular Disease.

International journal of drug discovery and pharmacology·2025
Same journal

Integrins as Drug Targets in Vascular and Related Diseases.

International journal of drug discovery and pharmacology·2024
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

872

Rho/ROCK Pathway as a Therapeutic Target in Multiple Diseases.

Zixiu Cheng1, Shannon Erhardt1,2, Jun Wang1,2

  • 1Department of Pediatrics, McGovern Medical School at UTHealth, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

International Journal of Drug Discovery and Pharmacology
|December 11, 2025
PubMed
Summary
This summary is machine-generated.

The Rho/ROCK signaling pathway regulates key cellular functions. Targeting this pathway with ROCK inhibitors shows therapeutic promise for diseases like cancer and cardiovascular disorders.

Keywords:
ROCKRhodrug-targetingfibrosis

Related Experiment Videos

Last Updated: Jan 9, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

872

Area of Science:

  • Molecular Biology
  • Cellular Biology
  • Pharmacology

Background:

  • The Rho/ROCK signaling pathway is crucial for cellular processes like cytoskeletal organization, migration, proliferation, and apoptosis.
  • Aberrant Rho/ROCK signaling is linked to the development of cardiovascular disorders, cancer, neurological conditions, and fibrotic diseases.

Purpose of the Study:

  • To summarize the molecular mechanisms of Rho/ROCK signaling.
  • To explore the role of Rho/ROCK in disease pathogenesis.
  • To discuss the therapeutic potential of ROCK inhibitors.

Main Methods:

  • Literature review of molecular mechanisms.
  • Analysis of Rho/ROCK pathway's role in various diseases.
  • Review of current ROCK inhibitor development and clinical applications.

Main Results:

  • Rho/ROCK signaling controls fundamental cellular activities.
  • Dysregulation contributes to multiple pathologies.
  • ROCK inhibitors are under active investigation and clinical development.

Conclusions:

  • Targeting the Rho/ROCK pathway offers a promising therapeutic strategy.
  • ROCK inhibitors represent a significant advancement in treating diseases associated with pathway dysregulation.